Chen, MD, Chief Medical Officer Number Of Employees: ~59 Stage: Publicly traded Financial Snapshot: The companys market cap as of July 2026 is $4.39 billion Key Products: VK2735 (subcutaneous), dual GLP-1/GIP receptor agonist in
Exercise : Include strength training at least 23 times per week to preserve muscle mass
Disclosure: Im a paid contributor to NutritionNC.com and was not compensated by Mochi for this review
Based on the drugstore you opt to visit, on average the Rybelus price is a strength of 3mg for a supply of 30 tablets ranging between $1025-$1200
What can be said factually is that retatrutide is the one major GLP-1 with no legitimate, approved, or compounded supply anywhere, which means there is no safer tier to choose instead, only the clinical trial or the gray market
Youll then work with a dedicated clinician to create a personalized care plan, which may include medications